Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelinkâ„¢ degrader antibody conjugate platform.
Gilead Sciences has commended the leadership of the South African Government and the Global Fund for accelerating early access to its long-acting HIV prevention medication, lenacapavir.
Novo Nordisk has expanded global access to obesity care by launching the once-daily Wegovy pill in the United Arab Emirates, offering a non-injectable alternative with a 17% mean weight loss and MACE risk reduction.
GSK is set to demonstrate the strength of its oncology pipeline at major 2026 congresses, highlighting long-term outcomes for Jemperli and Blenrep alongside new GIST data.
Eli Lilly infectious disease acquisitions have officially signaled a new era for Eli Lilly and Company as they aggressively expand their footprint in the anti-infective [Read More…]
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
GenScript has launched the TurboCHOâ„¢ Protein Expression Kit in Boston, offering researchers the fastest path to high-titer antibodies with a proprietary transfection system and high-performing CHO cell line.
Charles River Laboratories First Quarter 2026 Results were officially released, showcasing a company in the midst of a significant strategic transformation. The Wilmington-based contract research [Read More…]
Gilead Sciences reports a strong Q1 2026 with $6.96 billion in revenue, driven by its industry-leading HIV portfolio and the rapid uptake of Yeztugo, despite acquisition-related guidance adjustments.
Released in May 2026, the Novo Nordisk Q1 2026 report showcases a complex but optimistic financial picture, highlighting a massive revenue beat fueled by the record-breaking U.S. launch of the Wegovy pill, prompting the pharmaceutical giant to raise its full-year guidance.
